Saturday, 5 September 2026European Markets

BALYO Stock Bullish By 27% In The Last 21 Sessions

Loading stream...

(vianews) - shares of balyo (cac 40: balyo.pa) jumped by a staggering 27.83% in 21 sessions from €0.62 to €0.79 at 16:53 est on monday, following the last session's downward trend. cac 40 is sliding 2.69% to €7,026.37, after four consecutive sessions in a row of losses.

balyo's last close was €0.83, 34.47% under its 52-week high of €1.26.

about balyo

balyo sa designs, develops, and markets material handling robots worldwide. the company offers robotic pallet and reach trucks, tuggers, stackers, counterbalanced stackers, very narrow aisles, and autonomous mobile robots. its products are used in intelligent pallet detection, barcode scanning, inter-building transport, push button configuration, machine interface, erp interfacing, and palletizers; and wms interface and 3d camera applications. the company serves 3pl, automotive, e-commerce, and consumer goods industries. balyo sa was founded in 2004 and is headquartered in arcueil, france.

earnings per share

as for profitability, balyo has a trailing twelve months eps of €-0.18.

more news about balyo (balyo.pa).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI Capital Surge Meets Investor Caution: Record Funding Rounds and Government Contracts Amid Valuation Skepticism
A single-week cluster of large AI/fintech funding rounds (Socure, Stability AI, Emerald AI, Generalist AI, Instinct, Gatik, Regent Craft) shows venture capital still pouring into AI infrastructure, identity, and autonomy plays, while Palantir's Army TITAN contract win coincided with a 6% stock drop — signaling that even flagship AI-defense revenue isn't immune to market reassessment of AI valuations. Efficiency-focused innovations like Multiverse Computing's model compression suggest the sector is also pivoting toward cost/inference economics as capital intensity draws scrutiny.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Morgan Stanley & Co. LLC
The same metric (eps) for the same entity (Morgan Stanley & Co. LLC) reported for the identical fiscal period (Q1 2026) and observation date (2026-03-31) has two conflicting values: 3.43 USD_per_share vs 3.08 USD. This is not a temporal change — both observations claim to measure the same point in time. The ~10% discrepancy (0.35 USD difference) is material for a financial metric.
We flag conflicts openly ›
Recently verified
Checked against the original source
4,981
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,981 facts checked against source5,273 source documents archived
Query this data → isubstrate.com